These findings support further clinical investigation of VEGF-A-modified mRNA as an angiogenic therapy not only in patients with peripheral ischemia associated with T2DM but also in those with ischemic cardiovascular diseases. This evidence concerns the gene VEGFA and type 2 diabetes mellitus.